Skip to main content

Market Overview

Syndax Pharmaceuticals: Q4 Earnings Insights


Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 0.00% year over year to ($0.44), which beat the estimate of ($0.49).

Revenue of $380,000 unchanged by 0.00% from the same period last year, which beat the estimate of $200,000.


Syndax Sees Q1 2021 R&D Expenses $25M-$30M; Sees Total Operating Expenses $30M-$35M
Syndax Pharmaceuticals Sees FY 2021 R&D Expenses $90M-$100M; Sees FY 2021 Total Operating Expenses $110M-$120M

Conference Call Details

Date: Mar 08, 2021

Time: 04:30 PM

ET Webcast URL:

Recent Stock Performance

52-week high: $27.85

Company's 52-week low was at $6.88

Price action over last quarter: Up 22.96%

Company Overview

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.


Related Articles (SNDX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings